Akero Therapeutics, Inc. (AKRO)

One of the best catalysts for sudden, sharp rise in the price of a stock is when the company behind it get acquired at a premium. Case in point: Akero Therapeutics (AKRO 16.33%), whose shares soared by more than 16% Thursday after it was revealed the biotech will have a new owner.

Major U.S. equities indexes pulled back Thursday after the S&P 500 and Nasdaq set fresh all-time highs. The Dow Jones Industrial Average, S&P 500, and Nasdaq all were lower at midday.

MILWAUKEE , Oct. 9, 2025 /PRNewswire/ -- The Ademi Firm is investigating Akero (NASDAQ: AKRO) for possible breaches of fiduciary duty and other violations of law in its transaction with Novo Nordisk. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.

Novo Nordisk said on Thursday it would buy U.S.-based Akero Therapeutics for up to $5.2 billion to add its promising experimental liver disease drug, in the first major deal by the Danish drugmaker's new CEO to boost growth.

Novo Nordisk A/S (NYSE:NVO) is down 1% to trade at $59 this morning, after news surfaced that the pharmaceutical concern has entered an agreement to purchase U.S.-based peer Akero Therapeutics Inc (NASDAQ:AKRO) for as much as $5.2 billion in cash.

Novo Nordisk A/S (NYSE:NVO) agreed on Thursday to acquire Akero Therapeutics, Inc. (NASDAQ:AKRO) focused on metabolic diseases.

Novo Nordisk (NYSE:NVO) announced it is acquiring Akero Therapeutics (NASDAQ: AKRO) for a total potential value of up to $5.2 billion, strengthening its pipeline in treatments for metabolic dysfunction-associated steatohepatitis (MASH) and related metabolic diseases. Under the terms of the agreement, Novo Nordisk will pay $54 per share in cash, valuing Akero at approximately $4.7 billion upfront.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Akero Therapeutics, Inc. (NASDAQ: AKRO) to Novo Nordisk A/S is fair to Akero shareholders. Under the terms of the proposed transaction, Akero shareholders will receive $54.00 per share in cash, and a non-transferable Contingent Value Right entitling its holder to receive a cash payment of $6.00 per share upon full U.S. regulatory approval of efruxifermin by June 30, 2031. Halper Sadeh.

Novo said it would buy Akero for $54 a share in cash and an additional $6 if it gets U.S. approval of Efruxifermin - it's treatment for fatty liver disease.

Novo said the acquisition of would contribute to its strategy to develop medicines for people living with diabetes, obesity and their associated comorbidities.

Danish drugmaker Novo Nordisk said on Thursday it had agreed to buy United States based Akero Therapeutics, a clinical-stage company developing innovative treatments for patients with serious metabolic diseases marked by a high unmet medical need.

Shareholders to Receive $54 Per Share in Cash and CVR of $6 Per Share  Advances Akero's Mission of Bringing Novel Therapies to Patients with High Unmet Medical Needs SOUTH SAN FRANCISCO, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (“Akero”) (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that it has entered into a definitive agreement to be acquired by Novo Nordisk A/S (“Novo Nordisk”) for up to $5.2 billion in cash.

SOUTH SAN FRANCISCO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced two upcoming oral presentations and a poster presentation at the 76th Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025 taking place November 7-11, 2025, in Washington, DC. The presentations will highlight findings from the 96-week Phase 2b SYMMETRY study evaluating the safety and efficacy of lead product candidate efruxifermin (EFX) in patients with compensated cirrhosis (F4c) due to metabolic dysfunction-associated steatohepatitis (MASH), along with insights from an AI-powered digital analysis of histology data from the 96-week Phase 2b HARMONY study in patients with pre-cirrhotic (F2-F3) MASH.

Here is how Akero Therapeutics, Inc. (AKRO) and Humana (HUM) have performed compared to their sector so far this year.

The volatile biotech industry has done reasonably well so far in 2025 amid the ongoing tariff saga. Most pharma/biotech bigwigs are now investing heavily in manufacturing plants/operations in the United States as the Trump administration threatened of levying heavy tariffs on pharmaceutical imports (upto 250%) in a bid to boost domestic production.

Akero Therapeutics, Inc. (NASDAQ:AKRO ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 10:45 AM EDT Company Participants Andrew Cheng - President, CEO & Director Conference Call Participants Michael Ulz - Morgan Stanley, Research Division Presentation Michael Ulz Equity Analyst All right. Well, good morning, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference.